Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 12/20 | 0.50 |
| ▸ | BCHE | P06276 | 9/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 7/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12047873 | 0.83 | LMNA (0.50) | NR4A2KMT2AHSP90AB1POLBLMNA | |
| SCHEMBL22791812 | 0.83 | LMNA (0.50) | NR4A2KMT2AHSP90AB1POLBLMNA | |
| SCHEMBL29445571 | 0.80 | APP (0.70) | KMT2AACHEBCHEGRIN1GRIN2A | |
| SCHEMBL12488031 | 0.80 | APP (0.70) | KMT2AACHEBCHEGRIN1GRIN2A | |
| SCHEMBL106725 | 0.80 | APP (0.70) | KMT2AACHEBCHEGRIN1GRIN2A | |
| SCHEMBL29365544 | 0.80 | APP (0.70) | KMT2AACHEBCHEGRIN1GRIN2A | |
| SCHEMBL7795994 | 0.80 | ACHE (0.67) | NR4A2KMT2AACHEBCHEGRIN1 | |
| SCHEMBL13696862 | 0.80 | ACHE (0.67) | KMT2AACHEBCHEGRIN1GRIN2A | |
| SCHEMBL16554120 | 0.77 | MEN1 (0.76) | KMT2APOLBLMNA | |
| SCHEMBL11055652 | 0.76 | ACHE (0.67) | KMT2AACHEBCHEGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086713-A1 | CGAS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | UNIVERSITY OF WASHINGTON | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086713-A1 | CGAS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | STING1, IRF3, CGAS | NR4A2 2932/4885KMT2A 3147/4885ACHE 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.